ライフサイエンスコーパス: angiosarcoma

1 mas, 0 of 1 hemangioendothelioma, and 0 of 1 angiosarcoma).

2 cells and a potential therapeutic target in angiosarcoma.

3 d with around a five-times increased risk of angiosarcoma.

4 ient returned with proven metastatic cardiac angiosarcoma.

5 th pazopanib alone in patients with advanced angiosarcoma.

6 metastasis, were enriched in mouse and human angiosarcoma.

7 0 506 women [54.5%]) with a new diagnosis of angiosarcoma.

8 he biological relevance of these pathways in angiosarcoma.

9 istologically and genetically resemble human angiosarcoma.

10 c changes underpinning primary and secondary angiosarcoma.

11 ogenesis signaling genes, as a key driver of angiosarcoma.

12 efforts to target angiogenesis signaling in angiosarcoma.

13 inhibition as a therapeutic avenue for HNFS angiosarcoma.

14 TAT3 pathway as a rational strategy to treat angiosarcoma.

15 gy and potential therapies for patients with angiosarcoma.

16 ises a large proportion of all patients with angiosarcoma.

17 t the radiologist to a possible diagnosis of angiosarcoma.

18 with particular susceptibility to aggressive angiosarcomas.

19 hich were histologically well-differentiated angiosarcomas.

20 features for optimal risk stratification in angiosarcomas.

21 athological and clinical features with human angiosarcomas.

22 mors are more aggressive than Ha-ras-induced angiosarcomas.

23 which are showing promise in the control of angiosarcomas.

24 ted in a variety of human cancers, including angiosarcomas.

25 carcinomas, MCF-7 breast carcinomas, and SVR angiosarcomas.

26 iagnosis, followed by fibrosarcoma (15%) and angiosarcoma (15%).

27 955) were cutaneous, subcutaneous, or breast angiosarcomas; 24.4% were visceral (n = 4701); and 3.3%

28 ORR was highest in angiosarcoma (3/8) and undifferentiated pleomorphic sarc

29 ignant disorders other than KS and NHL, only angiosarcoma (36.7-fold), Hodgkin's disease (7.6-fold),

30 Among breast angiosarcomas, 99.2% (2684 of 2705) were in women and 71

31 t can overcome these challenges, focusing on angiosarcoma, a sarcoma with an annual incidence of 300

32 The RR of angiosarcoma after anthracyclines was 3.6 (95% CI 1.0-13

33 ng from the liver hemangiomas, and extremity angiosarcomas all occur at a rate of less than 10%.

34 utophosphorylation of VEGFR2 and reported in angiosarcomas alongside other driver mutations.

35 ght the need for improved early detection of angiosarcoma among patients at high risk, such as women

36 lobal pesticide poisoning outbreaks, hepatic angiosarcoma among vinyl chloride workers, toxic oil syn

37 Secondary breast and chest wall angiosarcomas among women represented the largest contri

38 ssor gene deleted in many cancers, including angiosarcoma, an aggressive malignancy of endothelial ce

39 role in the pathobiology of KS and cutaneous angiosarcoma and identify additional potential targets f

40 In this review we discuss angiosarcoma and its current management, with a focus on

41 receptors play a role in the pathobiology of angiosarcoma and KS, we studied the expression of angiop

42 ity when using MB(V) compared with MB(C) for angiosarcoma and malignant glioma tumors (P < .001).

43 or lines of therapy were treated (0 to 3 for angiosarcoma and malignant peripheral-nerve sheath tumor

44 single agent, sorafenib has activity against angiosarcoma and minimal activity against other sarcomas

45 V/HHV8 sequences were found in 7 of 24 (29%) angiosarcomas and 1 of 20 (5%) hemangiomas but not in an

46 ubsequent thoracic soft tissue sarcomas (268 angiosarcomas and 162 other subtypes) after a median fol

47 Angiosarcomas and fibrohistiocytic tumors were most freq

48 sought to establish the molecular biology of angiosarcomas and identify specific targets for treatmen

49 was any second thoracic soft tissue sarcoma (angiosarcomas and other subtypes) that developed at leas

50 uamous cell carcinomas, adenocarcinomas, and angiosarcomas), and induced by various chemical and phys

51 Kaposi's sarcoma (KS), 2 cases of cutaneous angiosarcoma, and 6 cases of capillary hemangioma by in

52 angiosarcoma, demographics of patients with angiosarcoma, and extent of disease at presentation.

53 In comparison, leiomyoscarcomas, angiosarcomas, and fibrohistiocytic tumors comprised 16.

54 of angiopoietin-1 was seen in KS, cutaneous angiosarcomas, and in normal skin.

55 oid tumors, dermatofibrosarcoma protuberans, angiosarcomas, and prior or synchronous distant recurren

56 intravenously into nude mice (n = 4) bearing angiosarcomas, and the whole-body biodistribution of the

57 sociated Kaposi's sarcoma (KS) and cutaneous angiosarcoma are malignancies of endothelial origin.

58 sarcoma, malignant fibrous histiocytoma, and angiosarcoma are the most common types of sarcoma to occ

59 ronic lymphoedema and hence secondary breast angiosarcomas are an important subgroup.

60 Angiosarcomas are rare soft-tissue sarcomas of endotheli

61 Primary cardiac angiosarcomas are rare tumors with unfavorable prognosis

62 Angiosarcomas are rare vascular connective tissue tumors

63 Angiosarcomas are soft-tissue sarcomas that form maligna

64 Angiosarcomas are very rare, and due to their aggressive

65 greater susceptibility to VC-induced hepatic angiosarcoma as well as their particular susceptibility

66 ous radiation therapy (RT)-associated breast angiosarcoma (AS) is a rare consequence of breast RT ass

67 Angiosarcoma (AS) is a rare understudied soft tissue sar

68 th histology and genetics analogous to human angiosarcoma (AS), a rare and aggressive malignancy aris

69 Angiosarcomas (AS) represent a heterogeneous group of ma

70 ge cohort of 486 tumor specimens, comprising angiosarcomas (AS), Ewing sarcomas, leiomyosarcomas, mal

71 to paclitaxel once per week in treatment of angiosarcomas (AS).

72 Control studies in angiosarcoma-bearing mice were performed with injection

73 9 patients in the US with a new diagnosis of angiosarcoma between 2001 and 2020 captured in the USCS

74 ecapitulate genetic traits observed in human angiosarcoma, but also unveil a possible therapeutic lin

75 on a potential therapeutic strategy against angiosarcoma by combining a relatively low dose of cispl

76 Angiosarcoma cell lines were treated with the mitogen-ac

77 Using a panel of hemangioendothelioma and angiosarcoma cell lines, we demonstrate that beta adrene

78 ling with propranolol hydrochloride disrupts angiosarcoma cell survival and xenograft angiosarcoma pr

79 y phenotype genes are activated in senescent angiosarcoma cells and that ABT-263 treatment downregula

80 SVR angiosarcoma cells were grown in vivo and gene expressio

81 pathway is required for soft agar growth of angiosarcoma cells, and separates the phenotypes of soft

82 lation of ras-mediated tumor angiogenesis in angiosarcoma cells.

83 dominant negative MAPKK gene into SVR murine angiosarcoma cells.

84 ibitor trametinib decreased the viability of angiosarcoma cells.

85 reatment alone requires high doses to remove angiosarcoma cells.

86 paclitaxel efficiently induce senescence in angiosarcoma cells.

87 Incidence of angiosarcoma, demographics of patients with angiosarcoma

88 ully penetrant animal model for the study of angiosarcoma development and metastasis.

89 y in myeloid cells was insufficient to block angiosarcoma development; in contrast, systemic inhibiti

90 The US incidence of angiosarcoma doubled between 2001 (657 cases) and 2019 (

91 s underlying the activity of these agents in angiosarcoma, EHE, and HPC/SFT are poorly understood.

92 survival periods were generally low, several angiosarcoma, EHE, and HPC/SFT patients demonstrated res

93 effective therapy for certain patients with angiosarcoma, EHE, and HPC/SFT, but more studies are nee

94 developed a thoracic soft tissue sarcoma (11 angiosarcomas, eight other subtypes).

95 th factor (VEGF) and its receptor (VEGFR) in angiosarcoma, epithelioid hemangioendothelioma (EHE), an

96 Angiosarcoma, epithelioid hemangioendothelioma, and Kapo

97 m 12 AIDS patients, in biopsies of cutaneous angiosarcoma from two patients, and in control biopsies

98 The angiosarcomas generated from MS1 VEGF cells demonstrated

99 , an inhibitor of YAP, significantly reduced angiosarcoma growth in mice.

100 f Ikkbeta, IL-6, or Stat3 markedly inhibited angiosarcoma growth.

101 ergic-positive multifocal stage T2 cutaneous angiosarcoma (>/=20 cm) involving 80% of the scalp, left

102 Five of 37 patients with angiosarcoma had a partial response (response rate, 14%)

103 review revealed that two patients with HNFS angiosarcoma had received off-label therapeutic use of a

104 Although human angiosarcoma has been associated frequently with mutatio

105 us benign and malignant disorders, including angiosarcoma, hemangiomas, and solid tumors.

106 ld standard is the histological diagnosis of angiosarcoma; however, microscopic evaluation may be com

107 g expression of KDR by tumor cells in KS and angiosarcoma implies that VPF/VEGF may also have a direc

108 -naive patients with chemotherapy-refractory angiosarcoma in a phase 1/2 trial.

109 first major advancement in the treatment of angiosarcoma in decades.

110 vinyl chloride (VC) clearly induces hepatic angiosarcoma in humans and rodents, a causal association

111 vivo, honokiol was highly effective against angiosarcoma in nude mice.

112 Rates of secondary angiosarcoma in the abdomen and lower extremities were s

113 viral genome induces early-onset, aggressive angiosarcoma in transgenic mice.

114 the outbred Black Swiss background and more angiosarcomas in 129/SvJae chimeric mice.

115 imaging, and pathologic findings of mammary angiosarcomas in 24 patients.

116 The presence of KSHV/HHV8 in angiosarcomas in addition to classical KS also indicates

117 Angiosarcomas in aP2-Cre;Dicer1(Flox/-) mice histologica

118 the groundwork for a promising treatment of angiosarcomas in humans.

119 ected in the tumor cells of KS and cutaneous angiosarcomas, in contrast to the focal low-level expres

120 ith aP2-Cre drives aggressive and metastatic angiosarcoma independent of other genetically engineered

121 g in LSECs leads to spontaneous formation of angiosarcoma, indicating its role as a tumor suppressor

122 Angiosarcoma is a rare sarcoma subtype with a poor outco

123 Angiosarcoma is an aggressive malignancy of endothelial

124 Angiosarcoma is an aggressive malignancy that arises spo

125 Angiosarcoma is an aggressive soft-tissue sarcoma with a

126 Angiosarcoma is an aggressive vascular malignant neoplas

127 Angiosarcoma is an aggressive vascular sarcoma with an e

128 Here we report that malignant angiosarcoma is associated with high levels of RelA/NF-k

129 Cardiac angiosarcoma is the most common malignant cardiac tumor,

130 tudy of combined VEGFR and MEK inhibition in angiosarcoma is warranted.

131 on of signal output, which in papillomas and angiosarcomas is achieved via increased Hras-gene copy n

132 Angiosarcoma/lymphangiosarcoma is a rare malignancy with

133 troperitoneal leiomyosarcoma, osteosarcomas, angiosarcomas, malignant fibrous histiocytomas, malignan

134 Leiomyosarcoma and angiosarcoma may occur disproportionately in immunodefic

135 as appear causatively linked to EBV, whereas angiosarcomas might be correlated with an arteriovenous

136 vascular tumor growth was tested in a mouse angiosarcoma model, of which the tumor growth mimics the

137 ses per 1 000 000 person-years) and cases of angiosarcoma (n = 1159) were modestly lower than in 2019

138 Overall, 72.3% of cases of angiosarcoma (n = 13 955) were cutaneous, subcutaneous,

139 CI, 9.7 to 53.5) for evaluable patients with angiosarcoma (n = 18); 33.3% in visceral and 22.2% in cu

140 logy database who had a diagnosis of mammary angiosarcoma (n = 26) and who underwent preoperative ima

141 patients treated overall and by subtype: two angiosarcomas (n = 16), 0 Ewing (n = 13), one fibrosarco

142 st frequently reported sarcomas, followed by angiosarcomas (n = 23) and fibrohistiocytic tumors (n =

143 rformed in 28 tumor-bearing nude mice (mouse angiosarcoma, n = 18; rat malignant glioma, n = 10).

144 ggested that for the subset of patients with angiosarcoma of HNFS, ultraviolet damage may be a causat

145 Here two cases of primary angiosarcoma of the aorta are described that highlight i

146 Radiation-induced angiosarcoma of the breast is a rare and highly aggressi

147 greatest increase among women with secondary angiosarcoma of the chest, breast, and upper extremity.

148 Angiosarcoma of the head, neck, face and scalp (HNFS) wa

149 istologically distinct primary liver tumors (angiosarcoma of the liver (ASL), cholangiocarcinoma (CCA

150 for the development of the sentinel neoplasm angiosarcoma of the liver represent a model population f

151 cause specific p53 mutations in persons with angiosarcoma of the liver.

152 k of HCC, while vinyl chloride is a cause of angiosarcoma of the liver.

153 Angiosarcoma of the spleen could be suggested in the maj

154 Records of 12 cases of proved angiosarcoma of the spleen were accessed from the files

155 Patients with stage T2 multilesion angiosarcomas of the scalp and face that are larger than

156 nd developed portal hypertension and hepatic angiosarcoma over time.

157 ltiple mutations in angiogenesis pathways in angiosarcomas, particularly in vascular endothelial grow

158 This cross-sectional study describes angiosarcoma presentation patterns and incidence rates i

159 pts angiosarcoma cell survival and xenograft angiosarcoma progression.

160 Here we describe the development of the Angiosarcoma Project (ASCproject), an initiative enablin

161 at beta-blockade alone substantially reduced angiosarcoma proliferation and, in combination with stan

162 lar tumors such as hemangioendotheliomas and angiosarcomas, revealing beta 1, 2, and 3 receptors were

163 ng was found active in over half of clinical angiosarcoma samples.

164 GF, HIF1alpha, and c-Myc expression in human angiosarcoma samples.

165 set of nonhematolymphoid neoplasms including angiosarcoma, solitary fibrous tumors, epithelioid sarco

166 Consistently, human angiosarcomas specimens contained a significantly greate

167 imary, lymphoma, gastric, duodenal, bladder, angiosarcoma, squamous cell carcinoma, thyroid, adrenal,

168 Tumor cells in KS and angiosarcoma strongly expressed KDR but not flt-1 mRNA.

169 dorsal aorta and is reactivated in malignant angiosarcoma, suggesting a strong association of Wnt1 wi

170 The tumor type was angiosarcoma, suggesting that vascular tissues are predi

171 pecificity on cells expressing VEGFR2 (mouse angiosarcoma SVR cells) and control cells (mouse skeleta

172 123 patients 18 years or older with advanced angiosarcoma that was conducted between February 16, 201

173 3.0 [95% CI 2.4-3.8]; p<0.0001) and, for angiosarcomas, the RR for breast-conserving surgery plus

174 its presence in a significant proportion of angiosarcomas, this study extends the number of tumors a

175 In this study, we examine an alternative angiosarcoma treatment approach that combines chemothera

176 e regulation of AMF-R expression in a BALB/c angiosarcoma tumor system that allows investigation of c

177 Some angiosarcoma tumors, however, harbor specific activating

178 as a single agent in reducing the growth of angiosarcoma tumors.

179 pecific groups (liposarcoma, leiomyosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, syno

180 d hypertension as potential risk factors for angiosarcomas, warrant further investigation as potentia

181 vs Pazopanib Alone in Patients With Advanced Angiosarcoma was a multinational, multicenter, open-labe

182 The incidence rate of visceral angiosarcoma was also found to be increasing (1.5% per y

183 The presence of the virus in angiosarcoma was confirmed by direct sequencing of the p

184 comas, well-differentiated liposarcomas, and angiosarcomas were excluded.

185 carcinomas, 10 normal breast tissues, and 16 angiosarcomas were included.

186 ere observed predominantly in primary breast angiosarcoma, which suggested a therapeutic rationale.

187 These mice developed papillomas and angiosarcomas, which were associated with Hras(G12V) all

188 ven links between vascular malformations and angiosarcoma with activated Ras signaling, we sought to

189 expression and response in six patients with angiosarcoma with paired pre- and post-therapy biopsies.

190 LCgamma1 signaling besides KDR activation in angiosarcomas, with implications for VEGF/KDR targeted t

191 utility of treating vascular tumors, such as angiosarcomas, with S6K inhibitors.

192 olimus 3 mg/kg/d inhibited the growth of SVR angiosarcoma xenografts in mice by 46% (P = 0.04).